Hybrid Adenoviral Vector Systems for Personalized Medicine and Immune Response Monitoring
Legal Citation
Summary of the Inventive Concept
The present invention discloses a novel integration of adenoviral vectors derived from chimpanzee adenovirus AdY25 with distinct technologies such as blockchain, artificial intelligence, nanomaterials, and IoT-enabled biosensors to create powerful systems for personalized medicine and real-time immune response monitoring.
Background and Problem Solved
Traditional adenoviral vector-based vaccines have limitations in terms of efficacy, scalability, and patient response tracking. The original patent addressed some of these limitations by providing novel adenoviral vectors derived from chimpanzee adenovirus AdY25. However, there remains a need for more sophisticated systems that can integrate these vectors with emerging technologies to provide more effective and personalized treatments.
Detailed Description of the Inventive Concept
The inventive concept disclosed herein comprises a hybrid adenoviral vector system that combines the advantages of adenoviral vectors derived from chimpanzee adenovirus AdY25 with blockchain-based data management platforms, artificial intelligence-driven predictive modeling, nanomaterial-based delivery systems, and IoT-enabled biosensors. The system enables personalized medicine by tracking patient responses and optimizing treatment regimens in real-time. Additionally, the system can predict vaccine efficacy using a combination of adenoviral vector-based immunogenic compositions and artificial intelligence-driven predictive modeling.
Novelty and Inventive Step
The novelty of the present invention lies in the synergistic integration of adenoviral vectors with distinct technologies to create a more powerful system for personalized medicine and immune response monitoring. The inventive step resides in the recognition that these technologies can be combined in a way that provides a more effective and efficient system for vaccine development and patient treatment.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept may include the use of different adenoviral vectors, blockchain platforms, artificial intelligence algorithms, nanomaterials, and IoT-enabled biosensors. Variations of the system may also include the integration of additional technologies such as gene editing tools or synthetic biology approaches.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the fields of personalized medicine, vaccine development, and immune response monitoring. The target market includes pharmaceutical companies, biotechnology firms, and healthcare providers seeking to develop more effective and targeted treatments for various diseases and conditions.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K48/00 |
| C | C12 | C12N5/0606 |
| C | C12 | C12N7/00 |
| C | C12 | C12N15/86 |
| C | C12 | C12N2710/10021 |
| C | C12 | C12N2710/10042 |
| C | C12 | C12N2710/10044 |
| C | C12 | C12N2800/204 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biotechnology and vaccine development, specifically focusing on adenoviral vector design, immunogenic compositions, and advanced medical technologies with expertise in molecular biology, virology, and bioengineering
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in molecular biology or bioengineering, familiar with adenoviral vector technologies, vaccine design principles, and emerging interdisciplinary medical technologies, possessing knowledge of genetic engineering, immunology, and computational modeling techniques
Obviousness Rationale
A person having ordinary skill in the art would recognize that integrating adenoviral vector technologies with emerging digital and computational platforms represents a predictable extension of existing vaccine development strategies. The combination of blockchain, AI, nanomaterials, and IoT technologies with established adenoviral vector platforms follows a logical progression of technological convergence in personalized medicine. These integrations leverage well-understood principles of data management, predictive modeling, and targeted delivery to enhance existing vaccine development methodologies.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,640 |
|---|---|
| Title | Simian adenovirus and hybrid adenoviral vectors |
| Assignee(s) | OXFORD UNIVERSITY INNOVATION LIMITED |